June 27, 2016
Authored and Edited by David C. Seastrunk; Elliot C. Cook; Daniel F. Klodowski; Aaron L. Parker
In the 35 Final Written Decisions issued by the Patent Trial and Appeal Board in May, the Board cancelled 413 (74.28%) of the instituted claims and declined to cancel 94 (16.91%) of the instituted claims. Patent owners conceded 49 (8.81%) of the instituted claims through motions to amend or disclaimer.
On a per-case basis, no instituted or substitute claims survived in 25 (71.43%) of the decisions, all instituted claims survived in only three (8.57%) of the decisions, and a mixed outcome occurred in seven (20.00%) of the decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.
The following resources are also available on the AIA Blog:
Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients.
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.